§

Apotex Corp. v. Allergan, Inc.

13961828 (P.T.A.B. Dec. 16, 2015)
Apotex Corp. v. Allergan, Inc.

5 Cited authorities

  1. Section 317 - Settlement

    35 U.S.C. § 317   Cited 37 times   48 Legal Analyses
    Addressing continuation of IPR as to some petitioners after dismissal of others

  2. Section 42.73 - Judgment

    37 C.F.R. § 42.73   Cited 18 times   61 Legal Analyses
    Regarding judgments

  3. Section 42.2 - Definitions

    37 C.F.R. § 42.2   Cited 7 times   11 Legal Analyses
    Defining "party" as "at least the petitioner and the patent owner"

  4. Section 42.74 - Settlement

    37 C.F.R. § 42.74   Cited 3 times   13 Legal Analyses

    (a)Board role. The parties may agree to settle any issue in a proceeding, but the Board is not a party to the settlement and may independently determine any question of jurisdiction, patentability, or Office practice. (b)Agreements in writing. Any agreement or understanding between the parties made in connection with, or in contemplation of, the termination of a proceeding shall be in writing and a true copy shall be filed with the Board before the termination of the trial. (c)Request to keep separate

  5. Section 42.72 - Termination of trial

    37 C.F.R. § 42.72   Cited 2 times   16 Legal Analyses

    The Board may terminate a trial without rendering a final written decision, where appropriate, including where the trial is consolidated with another proceeding or pursuant to a joint request under 35 U.S.C. 317(a) or 327(a) . 37 C.F.R. §42.72